Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
Go back to Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression| LIPOCINE (NASDAQ: LPCN) | Delayed: 2.53 +0.24 (10.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.29 | 52 Week High | $14.80 | |||
| Open | $2.24 | 52 Week Low | $2.51 | |||
| Day High | $2.67 | P/E | N/A | |||
| Day Low | $2.24 | EPS | $-0.69 | |||
| Volume | 207,822 | |||||
